Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VHB937 in Early Alzheimer's Disease
NCT07094516Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2025
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of VHB937 in Alzheimer's disease (AD), sponsored by Novartis. Started Aug 2025; status: active, not recruiting.
02
Drugs
VHB937
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07094516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07094516.